Faeth Therapeutics (FTH) Financials
Ticker history: SNSE became FTH (Faeth Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View SNSE history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FTH SEC filings page.
This page shows Faeth Therapeutics, Inc. (FTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
The company is shrinking its balance sheet while losses continue, with nearly all reported earnings loss translating into operating cash outflow.
The 49.5% asset contraction outpaced the38.2% liability contraction, so balance-sheet shrinkage was not simply debt paydown. Equity also fell51.6% , linking the smaller asset base to accumulated losses rather than a cleaner funding mix.
In FY2025, net loss was
The current ratio was 5.1x in FY2025 versus 7.7x in FY2024, showing short-term coverage remained high despite deterioration. Current assets contracted
Financial Health Signals
We do not publish a peer-relative financial health score for Faeth Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Faeth Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Faeth Therapeutics, Inc. reported a net loss of $21.1M while operations used $20.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Faeth Therapeutics, Inc. reported an operating loss of $22.3M against $32K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Faeth Therapeutics, Inc.'s EBITDA was -$22.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Faeth Therapeutics, Inc. reported a net loss of $20.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Faeth Therapeutics, Inc. recorded an outflow of $13.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Faeth Therapeutics, Inc. held $14.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Faeth Therapeutics, Inc.'s quarterly ROE was -12.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 7.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.4 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Faeth Therapeutics, Inc. invested $3K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
FTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $10.3M+347.1% | $9.2M+244.4% | $19.7M+455.5% | $2.8M-1.5% | $2.3M-27.3% | $2.7M-16.5% | $3.5M-6.9% | $2.8M-22.3% |
| Operating Income | -$22.1Mn/m | -$18.4Mn/m | -$170.6Mn/m | -$5.0Mn/m | -$4.9Mn/m | -$5.2Mn/m | -$7.3Mn/m | -$8.3Mn/m |
| EBITDA | -$22.1Mn/m | -$18.4Mn/m | -$170.6Mn/m | N/A | -$4.8Mn/m | -$5.2Mn/m | -$7.2Mn/m | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | $6K-71.4% | $10K-58.3% | $13K-53.6% | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0n/m | N/A |
| Net Income | -$20.4Mn/m | -$16.0Mn/m | -$170.2Mn/m | -$4.7Mn/m | -$4.6Mn/m | -$4.9Mn/m | -$6.9Mn/m | -$7.8Mn/m |
| EPS (Basic) | -$0.79 | -$2.84 | -$131.45 | -$3.74 | -$3.62 | -$3.91 | -$5.45 | -$0.31n/m |
| EPS (Diluted) | -$0.79 | -$2.84 | -$131.45 | -$3.74 | -$3.62 | -$3.91 | -$5.45 | -$0.31n/m |
| Diluted Shares (Avg) | 26M | 6M | 1M | N/A | 1M | 1M | 1M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses.
FTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $178.9M+548.6% | $189.3M+495.6% | $205.4M+436.6% | $22.9M-49.5% | $27.6M-48.2% | $31.8M-46.9% | $38.3M-42.6% | $45.4M-39.0% |
| Current Assets | $177.8M+589.7% | $188.7M+538.0% | $204.2M+472.4% | $21.5M-48.7% | $25.8M-46.4% | $29.6M-45.2% | $35.7M-40.8% | $41.9M-37.7% |
| Cash & Equivalents | $14.2M+34.3% | $26.9M+114.2% | $152.3M+1442.2% | $8.7M-13.3% | $10.6M-44.8% | $12.6M+5.6% | $9.9M-9.8% | $10.0M-23.2% |
| Short-Term Investments | $160.6M+1009.3% | $159.5M+892.7% | $50.5M+106.4% | $12.5M-60.1% | $14.5M-48.0% | $16.1M-60.2% | $24.5M-48.1% | $31.3M-40.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $11.1M+141.9% | $9.6M+114.4% | $342.7M+5351.3% | $4.3M-38.2% | $4.6M-38.7% | $4.5M-41.3% | $6.3M-23.5% | $7.0M-26.4% |
| Current Liabilities | $11.0M+148.7% | $9.6M+147.4% | $14.2M+171.4% | $4.3M-22.0% | $4.4M-18.5% | $3.9M-21.7% | $5.2M+4.7% | $5.4M-3.5% |
| Non-Current Liabilities | $53K-63.7% | $1K-99.8% | $328.5M+30976.3% | $59K-96.1% | $146K-92.8% | $596K-77.6% | $1.1M-67.3% | $1.5M-60.2% |
| Total Equity | $161.1M+600.2% | $173.0M+533.2% | -$137.3M-529.2% | $18.6M-51.6% | $23.0M-49.7% | $27.3M-47.7% | $32.0M-45.3% | $38.4M-40.8% |
| Retained Earnings | -$489.8Mn/m | -$469.4Mn/m | -$453.4Mn/m | -$283.1Mn/m | -$278.4Mn/m | -$273.9Mn/m | -$268.9Mn/m | -$262.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
FTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.0Mn/m | -$15.7Mn/m | -$10.7Mn/m | -$3.9Mn/m | -$3.6Mn/m | -$5.9Mn/m | -$7.1Mn/m | -$5.8Mn/m |
| Depreciation & Amortization | $17K-43.3% | $25K-21.9% | $29K-3.3% | $30K-78.4% | $30K-78.6% | $32K-76.3% | $30K-78.1% | $139K+3.0% |
| Stock-Based Compensation | $8.5M+3255.1% | $4.5M+1598.1% | $12.9M+2697.8% | N/A | $254K-65.3% | $264K-66.8% | $461K-62.1% | N/A |
| Capital Expenditures | $3Kn/m | $0-100.0% | $6Kn/m | $0n/m | $0n/m | $16K-85.3% | $0-100.0% | $0n/m |
| Free Cash Flow | -$13.0Mn/m | -$15.7Mn/m | -$10.7Mn/m | -$3.9Mn/m | -$3.6Mn/m | -$5.9Mn/m | -$7.1Mn/m | -$5.8Mn/m |
| Investing Cash Flow | $175K-90.0% | -$108.1M-1334.1% | -$31.4M-537.2% | $2.1Mn/m | $1.7M-86.5% | $8.8M+26.8% | $7.2M+24.6% | -$3.2M-138.1% |
| Financing Cash Flow | $104Kn/m | -$1.7Mn/m | $185.8Mn/m | -$111Kn/m | -$152Kn/m | -$168Kn/m | -$214Kn/m | -$194Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
FTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25Filing | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -12.7%+7.2pp | -9.3%+8.8pp | N/A | -25.4%-5.1pp | -19.9%-4.0pp | -18.1%-4.4pp | -21.5%-7.8pp | -20.2%-8.8pp |
| Return on Assets | -11.4%+5.2pp | -8.5%+7.1pp | -82.9%-65.0pp | -20.6%-3.5pp | -16.6%-2.9pp | -15.5%-3.6pp | -17.9%-5.9pp | -17.1%-7.2pp |
| Current Ratio | 16.12+10.3x | 19.69+12.1x | 14.39+7.6x | 5.06-2.6x | 5.81-3.0x | 7.64-3.3x | 6.82-5.2x | 7.70-4.2x |
| Liabilities-to-Equity | 0.07-0.1x | 0.06-0.1x | N/A | 0.23+0.1x | 0.200.0x | 0.160.0x | 0.20+0.1x | 0.180.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. FTH | FY2025 | N/A | -$21.1M | N/A | $514.8M | — |
| Neurogene, Inc. NGNE | FY2025 | $0 | -$90.4M | N/A | $513.3M | — |
| Entera Bio Ltd. ENTX | FY2025 | $42K | -$11.4M | N/A | $520.0M | — |
| Puma Biotechnology Inc PBYI | FY2025 | $228.4M | $31.1M | 13.6% | $504.3M | 68/100 |
| Valneva SE VALN | FY2025 | $205.0M | -$135.2M | -66.0% | $536.5M | 63/100 |
| Capricor Therapeutics Inc CAPR | FY2025 | $0 | -$105.0M | N/A | $500.0M | — |
Where Faeth Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Faeth Therapeutics, Inc. (FTH) reported a net loss of $211.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $21.1M.
Faeth Therapeutics, Inc. (FTH) had EBITDA of -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Faeth Therapeutics, Inc. (FTH) has a return on equity of -113.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Faeth Therapeutics, Inc. (FTH) recorded an outflow of $20.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Faeth Therapeutics, Inc. (FTH) recorded an outflow of $20.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Faeth Therapeutics, Inc. (FTH) had $22.9M in total assets as of fiscal year 2025, including both current and long-term assets.
Faeth Therapeutics, Inc. (FTH) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Faeth Therapeutics, Inc. (FTH) had a current ratio of 5.06 as of fiscal year 2025, which is generally considered healthy.
Faeth Therapeutics, Inc. (FTH) had a liabilities-to-equity ratio of 0.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Faeth Therapeutics, Inc. (FTH) had a return on assets of -92.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Faeth Therapeutics, Inc. (FTH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $514.8M as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Faeth Therapeutics, Inc. (FTH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $514.8M as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Faeth Therapeutics, Inc. (FTH) held $21.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $20.5M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Faeth Therapeutics, Inc. (FTH) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Faeth Therapeutics, Inc. (FTH) reported a net loss of $21.1M while operations used $20.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Faeth Therapeutics, Inc. (FTH) reported an operating loss of $22.3M against $32K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.